Protection against mammary tumor growth by vaccination with full- length, modified human ErbB-2 DNA

International Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 748-754

  Wei, Wei Zen ^a,c   Shi, Wei Ping ^a   Galy, Anne ^a   Lichlyter, Darcy ^a   Hernandez, Sonia ^a   Groner, Bernd ^b   Heilbrun, Lance ^a   Jones, Richard F ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE; DNA VACCINE; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; TUMOR VACCINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BREAST TUMOR; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; FEMALE; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH; VACCINATION;

AMINO ACID SUBSTITUTION; ANIMALS; CANCER VACCINES; CELL DIVISION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENES, ERBB-2; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; PLASMIDS; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; SEQUENCE DELETION; TRANSFECTION; TUMOR CELLS, CULTURED; TYROSINE; VACCINES, DNA;

EID: 0032952692     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6     Document Type: Article

References (30)

1. ARMSTRONG, T.D., CLEMENTS, V.K., MARTIN, B.K., TING, J.P.Y. and OSTRAND-ROSENBERG, S., Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. nat. Acad. Sci. (Wash.), 94, 6886-6891 (1997).
2. her2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. clin. Oncol., 14, 737-744 (1996).
3. BEN-LEVY, R., PATERSON, H.F., MARSHALL, C.J. and YARDEN, Y., A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J., 13, 3302-3311 (1994).
4. BENNETT, S., CARBONE, F.R., KARAMALIS, F., FLAVELL, R.A., MILLER, J.F.A.P. and HEATH, W.R., Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (Lond.), 393, 478-480 (1998).
5. CHEN, Y., HU, D., ELING, D.J., ROBBINS, J. and KIPPS, T.J., DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res., 58, 1965-1971 (1998).
6. CIERNIK, I.F., BERZOFSKY, J.A. and CARBONE, D.P., Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol., 156, 2369-2375 (1996).
7. CORR, M., LEE, D.J., CARSON, D.A. and TIGHE, H., Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. exp. Med., 184, 1555-1560 (1996).
8. DAVIS, M.M. and BJORKMAN, P.J., T-cell antigen receptor genes and T-cell recognition. Nature (Lond.), 334, 395-402 (1988).
9. DISIS, M., CALENOFF, E., MCLAUGHLIN, G., MURPHY, A.E., CHEN, W., GRONER, B., JESCHKE, M., LYDON, N., MCGLYNN, E., LIVINGSTON, R.B., MOE, R. and CHEEVER, M.A., Existent T cell and antibody immunity to Her-2/neu protein in patients with breast cancer. Cancer Res., 54, 16-20 (1994).
10. FENDLY, B.M., KOTTS, C., WONG, W.L.T., FIGARI, I., HAREL, W., STAIB, L., CARVER, M.E., VETTERLEIN, D., MITCHELL, M.S. and SHEPARD, H.M., Successful immunization of rhesus monkeys with the extracellular domain of p185HER2: a potential approach to human breast cancer. Vaccine Res., 2, 129-139 (1993).
11. FISK, B., ANDERSON, B.W., GRAVITT, K.R., O'BRIAN, C.A., KUDELKA, A.P., MURRAY, J.L., WHARTON, J.T. and IOANNIDES, C.G., Identification of naturally processed human ovarian peptides recognized by tumor-associated cytotoxic T lymphocytes. Cancer Res., 57, 87-95 (1997).
12. GRANT, E.P., MICHALEK, M.T., GOLDBERG, A.L. and ROCK, K.L., Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol., 155, 3750-3758 (1995).
13. IOANNIDES, C.G., FISK, B., FAN, D., BIDDISON, W.E., WHARTON, J.T. and O'BRIAN, C.A., Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the Her-2/neu proto-oncogene. Cell. Immunol., 151, 225-234 (1993).
14. IWASAKI, A., AURORA, C., TORRES, T., OHOSHI, P.S., ROBINSON, H.L. and BARBER, B.H., The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol., 159, 11-14 (1997).
15. KOZAK, M., Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 44, 283-292 (1986).
16. LUSTGARTEN, J., THEOBALD, M., LABADIE, C., LAFACE, D., PETERSON, P., DISIS, M.L., CHEEVER, M.A. and SHERMAN, L.A., Identification of her-2/ Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum. Immunol., 52, 109-118 (1997).
17. MAHONEY, K.H., MILLER, B.E., and HEPPNER, G.H., FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor associated macrophages from metastatic and nonmetastatic mouse mammary tumors. J. Leukocyte Biol., 38, 573-585 (1985).
18. MESSERLE, K., SCHLEGEL, J., HYNES, N.E. and GRONER, B., NIH/3T3 cells transformed with the activated ErbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative ErbB-2 variant. Mol. cell. Endocrinol., 105, 1-10 (1994).
19. MONACO, J.J., Pathways of antigen processing: a molecular model of MHC class-I-restricted antigen processing. Immunol. Today, 13, 173-176 (1992).
20. MULLER, W., SINN, E. and PATTENGALE, P., Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54, 105-115 (1988).
21. NEEFJES, J.J. and PLOEGH, H.L., Intracellular transport of MHC class II molecules. Immunol. Today, 13, 179-183 (1992).
22. PARDOLL, D.M. and BECKERIEG, A.M., Exposing the immunology of naked DNA vaccines. Immunity, 3, 165-169 (1995).
23. PEOPLES, G.E., GOEDEGEBUURE, P.S., SMITH, R., LINEHAN, D.C., YOSHINO, I. and EBERLEIN, T.J., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same Her-2/neu-derived peptide. Proc. nat. Acad. Sci. (Wash.), 92, 432-436 (1995).
24. PINKAS-KRAMARSKI, R., SOUSSAN, L., WATERMAN, H., LEVKOWITZ, G., ALROY, I., KLAPPER, L.N., LAVI, S., SEGER, R., RATZKIN, B.J., SELA, M. and YARDEN, Y., Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J., 15, 2452-2467 (1996).
25. RAMMENSEE, H.G., SCHILD, H. and THEOPOLD, U., Protein-specific cytotoxic T lymphocytes: recognition of transfectants expressing intracellular, membrane-associated or secreted forms of beta-galactosidase. Immunogenetics, 30, 296-302 (1989).
26. ROCK, K.L., GRAMM, C., ROTHSTEIN, L., CLARK, K., STEIN, R., DICK, L., HWANG, D. and GOLDBERG, A.L., Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78, 761-771 (1994).
27. SCHOENBERGER, S.P., TOES, R., VAN DER VOORT, E.I.H., OFFRINGA, R. and MELIEF, C.J., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (Lond.), 393, 480-483 (1998).
28. TZAHAR, E. and YARDEN, Y., The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochem. biophys. Acta, 1377, M25-M37 (1998).
29. 185neu protein and EGF receptor modulates EGF receptor function. Cell, 61, 1339-1347 (1990).
30. YOSHINO, I., GOEDGEBUURE, P.S., PEOPLES, G.E., PARIKH, A.S., DIMAIO, J.M., LYERLY, H.K., GAZDAR, A.F. and EBERLEIN, T.J., HER-2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res., 54, 3387-3390 (1994).